INTRODUCTION
Treatment of human epidermal growth factor receptor 2 (HER2) -positive and triple-negative breast cancers (TNBCs) with neoadjuvant therapy leads to pathologic complete response (pCR) rates of 30% to 50%, 1,2 which have been linked to long-term benefit. 3, 4 For TNBC, the use of platinum-based chemotherapy is currently under evaluation as a new chemotherapeutic option. 5, 6 However, a relevant number of patients still do not respond to treatment, and therefore, new treatment options are needed. Previous investigations have shown that immunologic parameters are relevant for response to neoadjuvant chemotherapy in BC 7-10 as well as for outcome after adjuvant therapy. [11] [12] [13] These immune signals are particularly strong in HER2-positive and TNBCs. 14, 15 Comparably high response rates were reported in initial clinical trials evaluating inhibitors of immune checkpoints, such as anti-PD-L1,
Statistical Analysis Plans
The investigations on TILs and mRNA markers were conducted as two separate translational research studies. The evaluation of TILs was part of the original study protocol of GeparSixto as a secondary end point. TILs were evaluated prospectively before random assignment, and the results were documented in a signed histopathologic report that was sent to the central study office for each patient. A prespecified statistical analysis plan for TIL evaluation was defined before statistical evaluation started.
The evaluation of mRNA markers was performed as a separate project using the existing tumor samples after the clinical study was completed. This separate project had a separate statistical analysis plan and study outline, which were also completely defined before the evaluation was started.
Prospective Histopathologic Evaluation of Inflammatory Infiltrates
TIL evaluation was performed on hematoxylin and eosin-stained sections in a routine diagnostic setting. 7 Each patient case was evaluated by two of six pathologists. We evaluated the percentage of stromal as well as intratumoral TILs separately. The predominant lymphocytic infiltrate was located in the stroma (Figs 1B to 1E) . Intratumoral TILs had lower levels and were correlated with stromal TILs (Appendix Fig A1, online only) . Therefore, in this analysis, we focused on stromal TILs as a continuous parameter. For some analyses, we used lymphocyte-predominant (LP) BC (Ն 60% of either intratumoral or stromal TILs) as a predefined categorical parameter, based on a previous study. 8 To evaluate interobserver variance of TIL assessment, three independent pathologists (C.D., B.M.P., W.D.S.) evaluated 87 digital images of selected regions from 29 tumors. The results were compared with automated image analysis.
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Evaluation of mRNA Markers
Immunologically relevant genes were selected based on previous evaluations 7 and published data on checkpoint inhibitors. [16] [17] [18] Total RNA was extracted from 5-m whole formalin-fixed paraffin-embedded sections with Ն 30% tumor area, as defined in a previous study, 23 using a fully automated method (VERSANT; Siemens, Tarrytown, NY).
24 Genes were measured in triplicate by quantitative real-time polymerase chain reaction (RT-PCR) using the SuperScript III Platinum One-Step quantitative RT-PCR system with ROX (Invitrogen, Karlsruhe, Germany) in a ViiA 7 RT-PCR system (Applied Biosystems, Darmstadt, Germany). The thermal profile included 30 minutes at 50°C, 20.5 minutes at 8°C and 2 minutes at 95°C followed by 40 cycles of 15 seconds at 95°C and 30 seconds at 60°C. Primer and probe sequences (Appendix Table A1 , online only) were selected by empiric rules and Primer Express software (version 3.0; Applied Biosystems). No-template controls, a standardized reference RNA control (Clontech Laboratories, Saint-Germain-en-Laye, France), and a pooled RNA control from TNBC samples (for CTLA4, FOXP3, and PD-1) were measured in parallel. Cycle threshold (Ct) values were calculated using ViiA 7 software (version 1.2.1; Applied Biosystems). Relative expression levels of genes of interest were calculated as ⌬Ct values (⌬Ct ϭ 20 Ϫ [Ct GOI Ϫ Ct (mean of RPL37A, CALM2, OAZ1) ]), where GOI indicates gene of interest. Trained laboratory personnel strictly blinded to clinical data performed all mRNA analyses after the end of the recruitment period.
Statistical Analyses
Associations between LPBC and pCR were investigated with 2 tests for categorical variables using SPSS software (version 21; SPSS, Chicago, IL) and with univariable logistic regression. Odds ratios (ORs) and 95% CIs with two-sided P values were used. A P value Յ .05 was considered statistically significant; no adjustment for multiple comparisons was performed. For the logistic regression, the following clinical variables were used: ER negative/PR negative versus ER positive and/or PR positive; HER2 positive versus HER2 negative; grade 3 versus grade 1 or 2; cT1-2 versus cT3-4; cN0 versus cNϩ; PM versus PM plus Cb; and age Ն 50 versus Ͻ 50 years. Stromal TILs were also included in an additional exploratory multivariable analysis of mRNA markers. An interaction test was performed for some analyses.
Interobserver variance was measured using Cohen's kappa and the intraclass correlation coefficient (ICC). 25 The ICC was calculated using the mixed model and absolute agreement. The ICC for single measures is an index for reliability of single raters, whereas the ICC for average measures is an index for reliability of different raters averaged together (which is similar to diagnostic approach used in GeparSixto); we report both ICC values.
pCR Rates in LPBC
Of the 580 patients, 142 (24.5%) had an LPBC phenotype (Figs 1B to 1D; Appendix Table A3 , online only), which was predictive for increased response to neoadjuvant chemotherapy. In the complete cohort, LPBC tumors had a pCR rate of 59.9%, compared with 33.8% for non-LPBC tumors (P Ͻ .001; Fig 1F) . The OR for prediction of pCR by LPBC was 2.92 (95% CI, 1.98 to 4.31; P Ͻ .001); this was in the same range as that for hormone receptor status (OR, 2.78; 95% CI, 1.84 to 4.20; P Ͻ .001; Table 1 ).
The percentage of stromal TILs (Fig 1D) was significantly linked to pCR, with an OR of 1.22 (95% CI, 1.14 to 1.31) per 10% increase in lymphocytes (P Ͻ .001; In a separate analysis for the two therapy arms (PM v PM plus Cb; Fig 1F) , pCR rates in patients with LPBC tumors were significantly higher with Cb therapy. In the LPBC subset, the addition of Cb increased the odds of pCR 3.71-fold, whereas in non-LPBCs, the increase was only 1.01-fold, leading to an interaction OR of 3.67 (Appendix Table A6 , online only). In TN and HER2-positive tumors with PMCb therapy, high response rates of 74% and 78% were observed for LPBC tumors; the test for interaction was significant in the complete cohort (P ϭ .002; Fig 1F) and in the HER2-positive (P ϭ .006; Fig 1H) parameter, the test for interaction with therapy was also positive in the complete cohort (P ϭ .006) and the HER2-positive subgroup (P ϭ .007; Table 2 ), but not in the TNBC subgroup (Appendix Tables A5  and A6 , online only).
In an exploratory logistic regression using the alternative pCR definition (ypT0is ypN0), stromal lymphocytes as well as LPBCs were still highly significant (stromal lymphocytes: OR, 1.19; 95% CI, 1.11 to 1.28; P Ͻ .001; LPBCs: OR, 2.83; 95% CI, 1.89 to 4.23; P Ͻ .001). With the wider pCR definition, the pCR rate of LPBC tumors with Cb treatment was 79% (for TNBC) and 85% (for HER2-positive BC). Using ypT0is ypN0 as an end point, the test for interaction between therapy and LPBC was still significant in the complete cohort Abbreviations: Cb, carboplatin; HER2, human epidermal growth factor 2; NS, nonsignificant; LPBC, lymphocyte-predominant breast cancer; OR, odds ratio; PM, paclitaxel plus nonpegylated liposomal doxorubicin; TIL, tumor-infiltrating lymphocyte; TNBC, triple-negative breast cancer.
(interaction P ϭ .009), but it was not significant in the TNBC or HER2-positive subgroup (data not shown).
Analytic Validation of TIL Assessment
To obtain data on interobserver variance of TIL assessment, three pathologists evaluated a set of digital images of 87 regions of interest from 29 tumors. For LPBC versus non-LPBC, Cohen's kappa values for comparison of the three evaluators with one another were 0.90, 0.69, and 0.60. For stromal TILs, the ICC for the 29 patient cases and three pathologists was 0.92 (95% CI, 0.83 to 0.96; P Ͻ .001) for single measures and 0.97 (95% CI, 0.93 to 0.99; P Ͻ .001) for average measures. Measurement of stromal TILs by automated image analysis showed that the lymphocytic infiltrate varied between Ͻ 500 and Ͼ 11,000 lymphocytes per mm 2 of stromal tissue (Appendix Fig A2,  online only) . The differences between the three observers were particularly relevant in those tumors with intermediate TIL levels between 20% and 50% that also showed increased intratumoral heterogeneity between the three regions of interest.
Evaluation of Immunologic mRNA Markers in Tumor Samples From GeparSixto
On the basis of previous reports by our group and others, we selected 12 immunologically relevant mRNA markers for detailed evaluation in breast cancer tissue, including T-cell markers, B-cell markers, chemokines, and immune checkpoint parameters (CXCL9, CCL5, CD8A, CD80, CXCL13, IGKC, CD21, IDO1, CTLA4, FOXP3) .
Hierarchic clustering of mRNA expression revealed three different immune subtypes of tumors with different expression of immunologic genes and different amounts of TILs (Fig 2A) . Immune group A tumors showed low expression of all immune genes, immune group C tumors had high immunologic gene expression levels, and immune group B tumors had intermediate gene expression levels. Similar patterns were observed in the HER2-positive and TN subgroups (Appendix Fig A3, online only) . The distribution of the three groups in the different subtypes is summarized in Appendix Table A3 (online only). The three immune subtypes had largely different response rates to chemotherapy. The pCR rates of immune groups A, B, and C were 24%, 37.4%, and 56.2%, respectively ( 2 test for trend P Ͻ .001; Fig  2B) . The percentages of LPBC tumors in immune groups A, B, and C were 1.1%, 19.1%, and 50.4%, respectively ( 2 test for trend P Ͻ .001; Fig 2B) .
All immune markers had highly significant (P Ͻ .001) positive correlations with one another and with stromal TILs (Appendix Fig A4, online only) . Interestingly, even those markers that were linked to immunosuppressive activity in tumor (Fig 2C;  Appendix Fig A4, online only) .
Prediction of Response to Neoadjuvant Chemotherapy by Immunologic mRNA Expression
All 12 immune mRNA markers were significantly linked to increased pCR (Table 3 ; Fig 3A) . The highest ORs were observed for PD-L1 (OR, 1.57 per ⌬Ct; 95% CI, 1.34 to 1.86; P Ͻ .001) and CCL5 (OR, 1.41 per ⌬Ct; 95% CI, 1.23 to 1.62; P Ͻ .001). The ORs were generally higher in HER2-positive compared with TN tumors (Figs 3B and 3C), which might be explained by an interaction of the immune system with the additional anti-HER2 therapy.
Eleven of the 12 mRNAs were also significant in multivariable analysis adjusted for clinicopathologic factors (Table 3) . As shown in Figures 3A to C, even putative immunosuppressive markers such as PD-1, PD-L1, CTLA4, and IDO1 had a positive correlation with chemotherapy response. The test for interaction with PM versus PMCb therapy was significant for CCL5 (P ϭ .002), CD8A (P ϭ .01), PD-1 (P ϭ .02), and IDO1 (P ϭ .03; Table 3 ). Inclusion of TILs and mRNA markers in a combined exploratory multivariable analysis demonstrated that pathologic as well as molecular parameters provided comparable information in many analyses (Table 3) . However, some mRNA markers, such as CCL5, PD-L1, and IDO1 in the complete cohort as well as PD-L1 and CD80 in TN tumors, were significant in multivariable analysis even if the stromal TILs were included. In TNBC, the markers CCL5, CD8A, and IDO1 provided predictive information for Cb response (test for interaction P ϭ .02 for CCL5; P ϭ .02 for CD8A; P ϭ .05 for IDO1; Table 3 ).
DISCUSSION
In this study, we performed a prospective validation of TILs in a large clinical trial. Two pathologists performed the analysis for each tumor at the time of random assignment in a setting that was comparable to routine diagnostic histopathology. Although a general positive role for TILs in chemotherapy response has been reported in many studies, [7] [8] [9] [10] 13 our study is the first to our knowledge to suggest that some types of chemotherapy, such as Cb, have a particularly strong interaction with the immune system. It has been shown that platinum chemotherapeutics have the ability to induce an immunogenic type of cell death, 26 which might explain the effects observed in our study. A recent study evaluating postneoadjuvant samples also described a role for immune cells in BC outcome.
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TILs in hematoxylin and eosin-stained sections are a basic parameter, considering the complexity of the immune system. Therefore, we further validated our results by investigation of mRNA expression of key modulators of immune reactions. All mRNA markers were significantly linked to pCR, and CCL5, CD8A, CTLA4, and IDO1 had a positive test for interaction with PM-plus-Cb versus PM chemotherapy. In TNBC, where stromal TILs had no significant interaction with PM-plus-Cb versus PM therapy, CCL5, IDO1, and CD8A had a significant test for interaction. Additional validations in larger cohorts are needed to validate mRNA signatures for additional predictive information beyond TILs.
Our evaluation included promising therapeutic targets such as CTLA4, PD-1, and PD-L1, which are already in clinical evaluation. [16] [17] [18] There is an ongoing debate about the best biomarkers for these new immunomodulatory therapies. In our study, mRNA markers such as PD-1, PD-L1, CTLA4, and FOXP3 showed a positive correlation with proimmune markers, stromal TILs, and treatment response. Immunosuppressive checkpoint markers were expressed in parallel with the proimmune markers, suggesting a feedback activation of immunosuppressive pathways as part of the immune reaction. Our results are concordant with a recent study by Schalper et al, 28 who showed that increased mRNA expression of PD-L1 was positively correlated with increased TILs as well as improved survival. The positive correlation of immunosuppressive markers with improved outcome and improved therapy response has been described in other studies as well.
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The cluster analysis shows that there are distinctive immunologic subtypes of BC and that a considerable amount of those tumors show features of immunogenicity. Therefore, it might be interesting to include certain types of BC in clinical evaluations of immunomodulatory agents. Such approaches might be able to change the intratumoral immune patterns observed in our hierarchic clustering and increase response rates to chemotherapy. More pCR Less pCR 
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There are some limitations to our study. We showed the interaction with Cb response for the specific comparison with the PM control arm in GeparSixto, and a validation in other clinical studies of Cb should be performed. The reduced pCR rate with PMCb in HER2-positive tumors with low TILs needs further validation, because this was not observed in the TNBC subcohort. We did not correct for multiple testing; however, the internal consistency of the results supports the conclusions regarding the relevance of immunologic interactions. It should be further noted that the TNBC and HER2-positive patient cohorts had somewhat uneven sample sizes and slightly different event rates, which translated into uneven power to detect markeroutcome associations for the same markers in the two distinct groups.
The analytic validation of TILs was not the main focus of this study and was just performed on a subset of samples. In this subset, the assessment of TILs by three observers had an ICC of 0.92 to 0.97. It is not clear at present if the methods for TIL evaluation would lead to similar results in a multicenter setting. However, even our singlecenter evaluation was performed by randomly assigned pathologists. Recently, a first guideline paper was published for further standardization of TIL evaluation.
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In summary, we prospectively validated the relevance of TILs and mRNA markers as response predictors in a large clinical trial. Interestingly, the effect size measured as OR was in a similar range for LPBC (OR, 2.92; 95% CI, 1.98 to 4.31; P Ͻ .001) and hormone receptor status (OR, 2.78; 95% CI, 1.84 to 4.20; P Ͻ .001). This suggests that after further international standardization, TILs could become an additional parameter for chemotherapy response prediction, with an importance similar to that of the established parameter of hormone receptor status.
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